The American Society of Retina Specialists (ASRS) is holding a virtual Annual Meeting this year, which will run for four days from this Friday.
On Saturday, David Boyer, MD, will be presenting Opthea’s Phase 2a DME trial results including primary and secondary outcomes - “Switching to Combination OPT-302 with Aflibercept from prior AntiVEGF-A Monotherapy in Eyes with Persistent Diabetic Macula Edema (DME)”.
Dr. David Boyer, a Senior Partner at Retina Vitreous Associates Medical Group, Los Angeles, and Clinical Professor at the University of Southern California Roski Eye Institute, Keck School of Medicine, was a study investigator on the trial.
https://www.asrs.org/content/documents/asrs-2020-annual-meeting-program_6.9.20.pdf
https://www.managedhealthcareexecutive.com/view/is-combination-therapy-on-the-horizon-in-dme
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-125
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
Add OPT (ASX) to my watchlist
|
|||||
Last
47.0¢ |
Change
0.025(5.62%) |
Mkt cap ! $578.6M |
Open | High | Low | Value | Volume |
44.0¢ | 47.0¢ | 42.5¢ | $1.327M | 2.960M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 63945 | 46.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 88685 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 63945 | 0.460 |
3 | 142677 | 0.455 |
4 | 113614 | 0.450 |
1 | 5617 | 0.445 |
1 | 22727 | 0.440 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 29000 | 1 |
0.490 | 2001 | 1 |
0.530 | 42475 | 1 |
0.570 | 9000 | 1 |
0.590 | 12001 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |